Ipilimumab After Allogeneic Stem Cell Transplant in Treating Patients With Persistent or Progressive Cancer
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying how well ipilimumab works after allogeneic stem cell
transplant in treating patients with persistent or progressive cancer. Monoclonal antibodies
can locate cancer cells and either kill them or deliver cancer-killing substances to them
without harming normal cells.